B
Biomea Fusion, Inc. (BMEA)
NMS – Real Time Price. Currency in USD
1.58
+0.01 (0.64%)
At close: May 12, 2026, 4:00 PM EDT
1.59
+0.01 (0.63%)
After-hours: May 12, 2026, 7:45 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.58
+0.01 (0.64%)
At close: May 12, 2026, 4:00 PM EDT
1.59
+0.01 (0.63%)
After-hours: May 12, 2026, 7:45 PM EDT
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
| Name | Position |
|---|---|
| Caroline Perez- Dupont J.D. | Senior Vice President of Contracts |
| Dr. Michael J. M. Hitchcock Ph.D. | Interim CEO & Director |
| Dr. Stephan Morris M.D. | Chief Development Officer |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Research |
| Mr. Heow Tan | Chief Technology & Quality Officer |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director |
| Mr. Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property |
| Date | Type | Document |
|---|---|---|
| 2026-04-28 | 8-K | d142809d8k.htm |
| 2026-04-27 | DEF 14A | bmea-20260427.htm |
| 2026-04-27 | ARS | ars_2025.pdf |
| 2026-03-24 | 10-K | bmea-20251231.htm |
| 2026-02-25 | 8-K | d95198d8k.htm |
| 2026-01-14 | 8-K | d747443d8k.htm |
| 2026-01-06 | S-8 | d10984ds8.htm |
| 2025-11-04 | 10-Q | bmea-20250930.htm |
| 2025-10-07 | 8-K | d237219d8k.htm |
| 2025-10-06 | 8-K | d79150d8k.htm |